THJ-2201
An indazole analogue of AM-2201, a full CB1 and CB2 agonist; US Schedule I as early as January 2015.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₃H₂₁FN₂O
CAS 1801552-01-1
- Family
- Synthetic CB receptor agonistNew psychoactive substance
- Molar mass
- 360.40 g/mol
Updated on
In plain terms
THJ-2201 is a synthetic cannabinoid made in a laboratory, a variant of AM-2201 in which the indole core is replaced by an indazole. It binds very strongly to the cannabis receptors in laboratory assays. It was placed in Schedule I in the United States in January 2015 and is classified as a narcotic in France.
Receptors and activity
Target network
- Activates
The lower the cited value, the closer the target sits to THJ-2201: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of THJ-2201.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1AgonistKi = 1.3 nM · human81 out of 100
Hess et al. 2016, Forensic Toxicol (new tab) · competitive [3H]CP55,940 binding, CHO cell membranes
- CB2AgonistKi = 1.3 nM · human81 out of 100
Hess et al. 2016, Forensic Toxicol (new tab) · competitive [3H]CP55,940 binding, CHO cell membranes
Pharmacology
THJ-2201 is a synthetic cannabinoid of the naphthoylindazole family: the analogue of AM-2201 in which the indole core is replaced by an indazole, and the fluorinated analogue of THJ-018, with which it was identified in 2014 (Diao et al. 2016). Hess et al. (2016) measure on human receptors Ki values of 1.34 nM at CB1 and 1.32 nM at CB2; Angerer et al. (2019) measure an EC50 of 1.68 nM at CB1 in a cAMP biosensor assay. According to Diao et al., the US forensic laboratory database held 220 reports of THJ-2201 and the US Drug Enforcement Administration placed it in Schedule I in January 2015 because of numerous adverse events. In human hepatocytes they observed 27 metabolites, dominated by oxidative defluorination followed by carboxylation or glucuronidation, in silico prediction underestimating this defluorination; in human liver microsomes, Gaunitz et al. (2019) describe 46. No controlled study in human beings was found.
Key sources.
- Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE. Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol. 2016;34:329-343 (new tab)PMID 27429655
- Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA. High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. Clin Chem. 2016;62(1):157-169 (new tab)PMID 26430074
- Angerer V, Franz F, Moosmann B, Bisel P, Auwärter V. 5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. Forensic Toxicol. 2019;37(1):186-196 (new tab)PMID 30636986
- Gaunitz F, Thomas A, Fietzke M, Franz F, Auwärter V, Thevis M. Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. Int J Legal Med. 2019;133(4):1049-1064 (new tab)PMID 30564916
- Council Framework Decision 2004/757/JHA, consolidated version of 12.01.2026 (annex: substances subject to Union control) (new tab)
History
- Source
- A wholly synthetic molecule, with no natural occurrence. It was identified in 2014, with THJ-018, as the indazole analogue of AM-2201 (Diao et al. 2016). None of this has anything to do with hemp or with cannabidiol products.
Origin
Laboratory synthesis
No biological pathway: THJ-2201 is entirely synthetic and belongs to the chemical family of the naphthoylindazoles.
Legal framework
- European Union
It does not appear in the annex to Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which names only five synthetic cannabinoid agonists: MDMB-CHMICA, ADB-CHMINACA, CUMYL-4CN-BINACA, MDMB-4en-PINACA and 4F-MDMB-BICA. Nor does it appear in annex III of the consolidated ANSM list (tables I and II of the 1971 Convention on Psychotropic Substances). Outside the Union, Diao et al. (2016) report that the US Drug Enforcement Administration placed it in Schedule I in January 2015, after numerous adverse events, the US forensic laboratory database then counting 220 reports.
- France
A narcotic in France, listed by name: the consolidated ANSM list (updated 16 February 2026) cites in annex IV « THJ-2201 ou [1-(5-Fluoropentyl)-1H-indazol-3-yl] (1-naphthyl) methanone », under the family of indazol-3-yl methanones, which covers molecules bearing on the nitrogen in position 1 of the indazole a substituent of the alkyl, haloalkyl, halobenzyl or related type and, on the carbon of the methanone bridge, a naphthyl, benzyl, phenyl, cyclopropyl or adamantyl group; the same list cites THJ-018.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Synthetic CB receptor agonist › New psychoactive substance
- Class
naphtoylindazole
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE. Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol. 2016;34:329-343 (new tab)PMID 27429655
- Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA. High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. Clin Chem. 2016;62(1):157-169 (new tab)PMID 26430074
- Angerer V, Franz F, Moosmann B, Bisel P, Auwärter V. 5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. Forensic Toxicol. 2019;37(1):186-196 (new tab)PMID 30636986
- Gaunitz F, Thomas A, Fietzke M, Franz F, Auwärter V, Thevis M. Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. Int J Legal Med. 2019;133(4):1049-1064 (new tab)PMID 30564916
- Council Framework Decision 2004/757/JHA, consolidated version of 12.01.2026 (annex: substances subject to Union control) (new tab)
Identifiers
Names
- IUPAC name
- [1-(5-fluoropentyl)indazol-3-yl]-naphthalen-1-ylmethanone
Identifiers
- Formula
- C₂₃H₂₁FN₂O
- CAS
- 1801552-01-1
- PubChem CID
- 91864533(new tab)
- InChIKey
- DULWRYKFTVFPTL-UHFFFAOYSA-N
- SMILES
- C1=
CC= C2C(= C1) C= CC= C2C(= O) C3= NN(C4= CC= CC= C43) CCCCCF
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.